Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • Cipla arm inks pact...

    Cipla arm inks pact for anti-psychotic drug Quetiapine

    Farhat NasimWritten by Farhat Nasim Published On 2020-02-11T12:15:11+05:30  |  Updated On 11 Feb 2020 12:15 PM IST
    Cipla arm inks pact for anti-psychotic drug Quetiapine

    New Delhi: Cipla Medpro South Africa (Pty) Ltd, a wholly-owned subsidiary of Cipla Ltd, India, has recently concluded an exclusive agreement securing originator and authorised generic brands of an atypical anti-psychotic drug Quetiapine.

    The agreement involves AstraZeneca Pharmaceuticals (Pty) Ltd, the originator of the medicine, and Luye Pharma Hong Kong Ltd, which acquired the assets and rights to the medicine in select territories.

    "The transaction allows Cipla Medpro to market and distribute the medicine in South Africa and neighbouring countries," a filing said on Monday.

    The existing portfolio consists of the originator brand Seroquel and the authorised generic brand Truvalin, a medication which is used to treat mental health conditions such as schizophrenia, bipolar disorder, and major depressive disorder, it added.

    Also Read: Cipla Acquires 4 Key Brands From Wanbury For Up To Rs 89 Crore

    Paul Miller, chief executive officer of Cipla South Africa, said the agreement strategically enhances Cipla''s Central Nervous System portfolio.

    "This transaction will help ensure that people have access to affordable and quality medicine that will help improve quality of life for people living with these conditions," he added.

    This partnership amplifies Cipla''s growing intent to partner with innovator companies and this is a further demonstration of our core competence in building and growing originator brands, ably strengthened by strong corporate governance and quality mindset, Miller said.

    Also Read: Cipla Q3 Revenue Up By 13pc At Rs 4371 Crore

    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok